Trulicity (dulaglutide)
Brand name dulaglutide. Easy auto-injector pen.
Trulicity (dulaglutide) is a once-weekly GLP-1 receptor agonist approved by the FDA in 2014 for type 2 diabetes. Its prefilled auto-injector is among the easiest GLP-1 devices to use.
Overview
Trulicity is dulaglutide, a long-acting GLP-1 produced by Eli Lilly. The molecule is built differently than semaglutide — dulaglutide is a fusion protein attaching GLP-1 to a modified IgG4 antibody fragment, extending half-life to about 5 days.
How Trulicity Works
Same GLP-1 receptor agonist mechanism. Modest weight loss as side benefit (~3-5 kg). Approved in 2020 for cardiovascular risk reduction based on REWIND trial.
Dosing & Schedule
Trulicity doses: 0.75 mg, 1.5 mg, 3.0 mg, 4.5 mg weekly. Single-use auto-injector pen — no dose dialing required.
Effectiveness — Trial Data
AWARD trials: A1c reduction 1.0-1.5% at 1.5 mg; about 0.4% additional reduction at 4.5 mg. Lower weight loss and A1c reduction than semaglutide or tirzepatide in head-to-head trials.
Side Effects
Nausea (12-21%), diarrhea, vomiting, abdominal pain, decreased appetite. Generally well tolerated.
Cost — How Much Trulicity Costs in 2026
Trulicity list price: $987/mo. Insurance widely covers for type 2 diabetes. No generic available.
Who Is Trulicity For?
Adults with type 2 diabetes, particularly those with cardiovascular risk. Children 10+ with type 2 diabetes (approved 2022).
Trulicity Alternatives
Alternatives: Ozempic (stronger), Mounjaro (dual agonist), generic liraglutide.